Replies to post #142774 on Biotech Values

[genisi]

Apropos to Zelboraf, the GSK BRAF inhibitor - dabrafenib has shown activity in brain metasteses, something I don't think was seen with Zelboraf:

http://abstract.asco.org/AbstView_114_97727.html